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Introduction
Thrombin Activatable Fibrinolysis Inhibitor - TAFI,
also called procarboxypeptidase B or carboxypepti-
dase U and carboxypeptidase R, is formed in the liver
as a unichain glycoprotein of molecular weight of 60
000 Da and circulates in the blood in the form of
zymogene (pro-TAFI). It is activated by the throm-
bin/thrombomodulin complex, functioning on the
walls of vessels (thrombomodulin exposed on the
endothelium is a receptor of thrombin and forms com-
plexes with it) [Fig. 1]. Activated pro-TAFI, that is
TAFIa (m.w. 35 000 Da), is a proteolytic enzyme
which changes the fibrin structure in such a way that
it becomes less susceptible to fibrinolysis. This phe-
nomenon consists in splitting off of C-final lysine and
arginine which decreases adsorption of tPA (tissue
plasminogen  activator) and plasminogen on fibrin,
leading in consequence to a decrease of plasmin gen-
eration and thus to prolongation of fibrinolysis [4,17].
TAFI is treated as a link connecting coagulation with
fibrinolysis [5]. Anti-inflammatory effect is another
property of TAFI [6]. TAFI has beneficial influence
on hemostasis, which is supposed to be an effect of
antifibrinolytic activity; this has been observed during
therapeutic application of recombined factor VIIa in
hemophilia [2,11]. Increased level of TAFI antigen
was described for many diseases. The increase of the
level of TAFI and of fibrinolysis inhibitor of type PAI-
1 in the coronary disease create together a high risk of
cardiac infarction [9,12]. In hepatocirrhosis the levels
of TAFI, antithrombin and alpha-2-antiplasmin go
down, which is explained by weaker synthesis
[10,15]. In disseminated intravascular coagulation
(DIC), TAFI level is lower, which can be a conse-
quence of consumption [18]. A lower level of TAFI
antigen was observed in women in severe preeclamp-
sia  and in intrauterine growth retardation syndrome
(IUGR) [1].  But nothing is known about TAFI in the
fetal blood. The aim of the present study was to find
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antecubital vein. 3.2% sodium citrate was used as an anticoagulant. TAFIa/ai antigen was measured by ELISA method.
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vs. 55.46 ng/ml (range: 39.77 - 68.54 ng/ml ) in the mother's blood, which means that the level of TAFIa/ai antigen was sig-
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Materials and method
Patients. The study groups consisted of 38 parturient women, at
the age of 21.3±3.2 years, including 26 primiparous and 12 multi-
parous with a single fetus and a physiological course of pregnancy
(cases with hypertension and restricted growth of the fetus were
excluded). The control group consisted of 20 healthy women of
21.1±0.9 of age, in the 18-25 day of menstrual cycle. All the
patients were informed about the aim of the study and gave their
permission for blood sampling. The permission of the Regional
Bioethics Committee was also obtained. 
Sampling of material. Cord blood was sampled immediately after
delivery of the fetus, before omphalotomy, by puncturing the cord
vein and aspirating blood into a syringe with 3.2% sodium citrate
(anticoagulant/blood proportion: 1:9). The blood was next trans-
ferred to a test-tube for centrifugation, put into water with ice and
taken to the laboratory where centrifugation was done (2000 × g
for 20 min, temp. +4°C). The blood plasma was put in test-tubes in
200 µl portions, tightly closed and kept until next examination 
(4-6 weeks) at -70°C. The maternal blood and the blood of women
from the control group was sampled from the antecubital vein and
then processed in the same way as described above for cord blood.
Measurement of the level of TAFI antigen. The TAFI antigen
level was measured using the immunoenzymatic (ELISA) method
with the laboratory kit IMUBIND TAFIa/ai Antigen ELISA
(American Diagnostica Inc.). That test measures TAFIa antigen
(active enzyme) and TAFIai antigen (inactivated enzyme).
According to the manufacturer, the sensitivity of that method is
10 ng/ml. In our laboratory the interassay and intraassay coeffi-
cients of variability were lower than 10%.
Statistical analysis. The program STATISTICA for Windows by
StatSoft was used for statistical analysis.
A characteristic feature of the AgTAFI variable in cord blood
and in the maternal blood was decomposition, different from nor-
mal, and that is why that variability was described by a median
(Me) and lower (Q1) and upper (Q3) quartiles. In the control group
the distribution of the feature under analysis was close to normal,
yet, for the uniformity of analysis it was also described as Me and
Q1 and Q3. The statistical analysis of dependent variables was
done with Friedman test. The value p<0.05 was adopted as a sta-
tistically significant level.
Results 
The level of TAFIa/ai antigen in cord blood was sta-
tistically significantly higher than in maternal blood
(p<0.0001). Accordingly, in cord blood  (n=38)  the
level was 91.50 ng/ml (median), range:  71.76 -
160.77 ng/ml (Q1-Q3)  vs. the level in the maternal
blood  (n=38): 55.46 ng/ml (median),  range: 39.77 -
68.54 ng/ml (Q1-Q3).
The level of TAFIa/ai antigen in the blood of the
control group (non pregnant women n=20) was
72.55 ng/ml, range: 67.50-76.69 ng/ml (Q1-Q3). It
was statistically significantly higher than in parturi-
ent women (p<0.0004). Fig. 2 presents those results
in a graphic form
Discussion
At the beginning of the discussion it seems appropriate
to comment on the terminology concerning TAFI. Not
so long ago, American and European authors used var-
ious terms. Now, the following unified terms are com-
monly used: pro - TAFI, i.e.  procarboxypeptidase B,
thus TAFI proenzyme; TAFIa is carboxypeptidase B in
the form of an active enzyme, while TAFIai  is the
inactivated form of carboxypeptidase B. In the present
study we measured the total level of TAFI antigen,
both as an active enzyme and as an inactivated enzyme
(TAFIa + TAFIai).
TAFI antigen was present in all samples of the
cord blood. We take that result to be evidence that
TAFI is an integral component of the blood. This is a
new observation. The total level of TAFI (TAFIa +
TAFIai) in the fetal blood is almost two times higher
than in the maternal blood (91.50 ng/ml vs. 55.46
ng/ml). But, as we demonstrated in our report at the
XXIII Congress of the Polish Gynecological Society,
the activity of TAFI in cord blood is about 50% lower
than in the maternal blood [16]. Most probably, the
inactivated TAFI (TAFIai) is a dominant component
of the total level. 
In contrast to research on fetal blood, the level of
the antigen and/or TAFI activity in the pregnant
women blood has been the subject of research of
many authors [1-3,7,8,13,19]. It has been found that
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Fig. 1. The mechanism of procarboxypepti-
dase B activation by thrombin/antithrombin
complex. * on the left side - thrombin for-
mation, and on the right side - TAFI forma-
tion, * TF - tissue factor, ** TAFI - throm-
bin activatable fibrinolysis inhibitor 
in the course of pregnancy the level of the antigen
and TAFI activity increase gradually, though moder-
ately. According to Chabloz et al. [7] the level of the
antigen in the third trimester of pregnancy constitutes
130% of the level in the first trimester; Mousa et al.
[13] found the level of the antigen to be 6.6±2 µg/ml
at the beginning of pregnancy, and 9.6±2 µg/ml in the
third trimester.
An increase of activity in the course of pregnancy
was also reported by Watanabe et al. [19], with plateau
on the 20th week. After delivery, already in the first
and second day, the level of the antigen and TAFI
activity falls down to the values found in non-pregnant
women [13,19].
It is not known what factors influence the increase
a relatively high level of TAFI in the fetus. It may be
due to an unknown role of that factor in the develop-
ment of the fetus? Likewise, it is not known when
TAFI appears in the fetal blood and when in the
extrauterine life the level drops down to that of adults.
It is possible that the increase of the level depends on
the high level of some of the hormones in the pregnant
woman's organism? Perhaps Chettaile et al. [8] pro-
vided an argument for such an assumption when they
reported an increase of the level of TAFI antigen in
women using oral contraceptives.
TAFI in maternal blood was not the target of our
study; maternal blood was only a reference point of
the gold standard type thanks to which we could
relate our results. It was important because the results
of other authors differ among each other (quantita-
tively, not qualitatively). Most probably, the cause of
those differences is the application of different mono-
or polyclonal antibodies, as well as insufficient stan-
dardization of measurements of TAFI in biological
fluids. There are reasons, then, to postulate further
studies.
Conclusions
Thrombin activatable fibrinolysis inhibitor (TAFI) is
an integral component of cord blood and it can be
identified in all samples of the cord blood. 
The level of thrombin activatable fibrinolysis
inhibitor (TAFI) is statistically significantly higher in
cord blood than in maternal blood (about two times
higher). 
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